Companies Vir Biotechnology, Inc.
Vir Biotechnology (VIR): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Vir Biotechnology, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers25th pct.Of 5 peer CEOs
CEO pay, last three years
- $7,834,045FY2025
CEO total pay was $7,834,045 in fiscal 2025; the brief holds no earlier figure for this CEO.
FY2025: salary $950,000 · bonus $0 · stock awards $2,296,800 · option awards $3,507,360
Executives and directors
Jason O'Byrne · CFOMarianne De Backer · CEOMark Eisner · EVPVanina de Verneuil · General CounselElliott Sigal · Independent DirectorGeorge Scangos · Former director (through FY2025)Janet Napolitano · Independent DirectorJeffrey S. Hatfield · Independent DirectorNorbert Bischofberger · Independent DirectorRamy Farid · Independent DirectorRobert More · Independent DirectorRobert Nelsen · Former director (through FY2025)Saira Ramasastry · Independent DirectorVicki Sato · Chair of the Board
Frequently asked questions
Who was the highest-paid executive at Vir Biotechnology, Inc. in fiscal 2025?
As disclosed, Marianne De Backer (President, Chief Executive Officer and Director) was the highest-paid executive at Vir Biotechnology, Inc. in fiscal 2025, with total compensation of $7,834,045.
How does Vir Biotechnology, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Marianne De Backer's total compensation ranked at the 25th percentile of Vir Biotechnology, Inc.'s disclosed peer group.
What is Vir Biotechnology, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Vir Biotechnology, Inc.'s CEO-to-median employee pay ratio was 24:1.
How did shareholders vote on Vir Biotechnology, Inc.'s executive compensation?
As disclosed, 90.14% of shareholders supported Vir Biotechnology, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Vir Biotechnology, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Vir Biotechnology, Inc. reported total board compensation of $1,020,304 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Marianne De Backer | $950,000 | $0 | $2,296,800 | $3,507,360 | $1,002,750 | $0 | $77,135 | $7,834,045 |
| President, Chief Executive Officer and Director | ||||||||
| Mark Eisner | 660,833 | 375,000 | 382,800 | 584,560 | 354,291 | 0 | 14,000 | 2,371,484 |
| Executive Vice President and Chief Medical Officer | ||||||||
| Jason O'Byrne | 534,417 | 150,000 | 382,800 | 584,560 | 286,051 | 0 | 14,000 | 1,951,828 |
| Executive Vice President and Chief Financial Officer | ||||||||
| Vanina de Verneuil | 506,333 | 0 | 334,950 | 511,490 | 329,648 | 0 | 8,363 | 1,690,784 |
| Executive Vice President, General Counsel and Corporate Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Marianne De Backer | $7,834,045 | — | — | — |
| Mark Eisner | 2,371,484 | 2,756,265 | — | ↓ −384,781 |
| Jason O'Byrne | 1,951,828 | 1,919,827 | — | ↑ +32,001 |
| Vanina de Verneuil | 1,690,784 | 1,669,471 | — | ↑ +21,313 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's compensation program is designed to attract, motivate, and retain executive officers by aligning their interests with those of stockholders through a mix of cash and equity-based compensation tied to corporate performance.
| CEO STI target (% of salary) | 80% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Semler Brossy |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Vanina de Verneuil | OPTION | 2025-02-22 | — | — | 70,000 | — | $511,490 |
| Marianne De Backer M.Sc. | OPTION | 2025-02-22 | — | — | 480,000 | — | 3,507,360 |
| Marianne De Backer M.Sc. | RSU | 2025-02-22 | — | — | 240,000 | — | 2,296,800 |
| Vanina de Verneuil | RSU | 2025-02-22 | — | — | 35,000 | — | 334,950 |
| Mark Eisner | OPTION | 2025-02-22 | — | — | 80,000 | — | 584,560 |
| Mark Eisner | RSU | 2025-02-22 | — | — | 40,000 | — | 382,800 |
| Jason O'Byrne | RSU | 2025-02-22 | — | — | 40,000 | — | 382,800 |
| Jason O'Byrne | OPTION | 2025-02-22 | — | — | 80,000 | — | 584,560 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Vanina de Verneuil | $334,950 | $0 | $511,490 | 0.0% |
| Marianne De Backer M.Sc. | 2,296,800 | 0 | 3,507,360 | 0.0% |
| Mark Eisner | 382,800 | 0 | 584,560 | 0.0% |
| Jason O'Byrne | 382,800 | 0 | 584,560 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Vanina de Verneuil | Option | 709 | 29.48 | — |
| Vanina de Verneuil | RSU | 2,125 | — | 12,814 |
| Vanina de Verneuil | RSU | 7,500 | — | 45,225 |
| Vanina de Verneuil | Option | 8,750 | 27.01 | — |
| Vanina de Verneuil | RSU | 9,524 | — | 57,430 |
| Vanina de Verneuil | Option | 14,375 | 10.04 | — |
| Vanina de Verneuil | RSU | 16,875 | — | 101,756 |
| Vanina de Verneuil | Option | 24,375 | 10.11 | — |
| Vanina de Verneuil | RSU | 35,000 | — | 211,050 |
| Mark Eisner | RSU | 40,000 | — | 241,200 |
| Jason O'Byrne | RSU | 40,000 | — | 241,200 |
| Mark Eisner | RSU | 56,250 | — | 339,188 |
| Jason O'Byrne | RSU | 56,250 | — | 339,188 |
| Vanina de Verneuil | Option | 70,000 | 9.57 | — |
| Mark Eisner | Option | 80,000 | 9.57 | — |
| Jason O'Byrne | Option | 80,000 | 9.57 | — |
| Mark Eisner | Option | 96,875 | 9.37 | — |
| Jason O'Byrne | Option | 109,375 | 8.64 | — |
| Marianne De Backer | RSU | 131,250 | — | 791,438 |
| Marianne De Backer | Option | 189,584 | 10.11 | — |
| Marianne De Backer | RSU | 240,000 | — | 1,447,200 |
| Marianne De Backer | RSU | 288,226 | — | 1,738,003 |
| Marianne De Backer | Option | 384,302 | 23.28 | — |
| Marianne De Backer | Option | 480,000 | 9.57 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Elliott SigalIndependent · Compensation · Science and Technology (Chair) | $90,030 | $39,520 | $57,955 | $0 | $0 | $187,505 |
| Vicki SatoIndependent · Board Chair · Nominating and Corporate Governance · Science and Technology · Not standing for re-election | 87,500 | 39,520 | 57,955 | 0 | 0 | 184,975 |
| Jeffrey S. HatfieldIndependent · Audit · Nominating and Corporate Governance (Chair) | 87,170 | 39,520 | 57,955 | 0 | 0 | 184,645 |
| Robert MoreIndependent · Audit · Compensation (Chair) | 85,385 | 39,520 | 57,955 | 0 | 0 | 182,860 |
| Saira RamasastryIndependent · Audit (Chair) | 82,651 | 39,520 | 57,955 | 0 | 0 | 180,126 |
| Norbert BischofbergerIndependent · Compensation · Science and Technology | 79,186 | 39,520 | 57,955 | 0 | 0 | 176,661 |
| Ramy FaridIndependent · Audit · Science and Technology | 67,500 | 39,520 | 57,955 | 0 | 0 | 164,975 |
| Janet NapolitanoIndependent · Compensation · Nominating and Corporate Governance | 62,500 | 39,520 | 57,955 | 0 | 0 | 159,975 |
| George ScangosIndependent · Science and Technology · Departed during FY | 39,557 | 0 | 0 | 0 | 0 | 39,557 |
| Robert NelsenIndependent · Nominating and Corporate Governance · Departed during FY | 22,665 | 0 | 0 | 0 | 0 | 22,665 |
| Marianne De BackerEmployee director · Nominating and Corporate Governance | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $385,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $704,144 |
| Equity awards (grant-date value) | $316,160 |
| All other compensation | $0 |
| Total cost of the board | $1,020,304 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Vir Biotechnology as a peer
Companies that benchmark against VIR
15 companies name VIR as a compensation peer
- AbCellera Biologics Inc.ABCLFY2025
- Allogene Therapeutics, Inc.ALLOFY2025
- Arcturus Therapeutics Holdings Inc.ARCTFY2025
- ARROWHEAD PHARMACEUTICALS, INC.ARWRFY2025
- Atea Pharmaceuticals, Inc.AVIRFY2025
- Biohaven Ltd.BHVNFY2025
- CRISPR Therapeutics AGCRSPFY2025
- Denali Therapeutics Inc.DNLIFY2025
- DYNAVAX TECHNOLOGIES CORPDVAXFY2024
- Ginkgo Bioworks Holdings, Inc.DNAFY2025
- Intellia Therapeutics, Inc.NTLAFY2025
- NOVAVAX INCNVAXFY2025
- Olema Pharmaceuticals, Inc.OLMAFY2025
- Relay Therapeutics, Inc.RLAYFY2025
- SOLENO THERAPEUTICS INCSLNOFY2024
Each company listed discloses VIR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named VIR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | BridgeBio Pharma | 2025 | Neil Kumar | $1,044,000 | $10,606,275 | $1,874,992 | $0 | $14,944,585 |
| 2 | Janux Therapeutics | 2025 | David Campbell | 680,000 | 0 | 12,459,031 | 367,200 | 13,506,231 |
| 3 | Apellis | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 4 | Vir Biotechnology, Inc. | 2025 | Marianne De Backer | 950,000 | 2,296,800 | 3,507,360 | 1,002,750 | 7,834,045 |
| 5 | Replimune Group | 2026 | Sushil Patel | 700,000 | 3,376,003 | 1,448,325 | 315,000 | 5,845,982 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Vir Biotechnology, Inc. | 125% | Options 67 · RSU 33 | not disclosed | Semler Brossy |
| Apellis | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| BridgeBio Pharma | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| Janux Therapeutics | 90% | not disclosed | not disclosed | FW Cook |
| Replimune Group | not disclosed | not disclosed | No | Pearl Meyer |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-26 | 108,453,963 | 11,863,405 | 1,372,563 | 90.14% | Passed |
| 2025 | 2025-05-29 | 100,486,810 | 4,280,297 | 151,748 | 95.91% | Passed |
| 2024 | 2024-05-29 | 83,922,789 | 22,639,307 | 158,331 | 78.64% | Passed |
| 2023 | 2023-05-19 | 106,031,723 | 4,377,092 | 97,048 | 95.95% | Passed |
| 2022 | 2022-05-20 | 94,041,769 | 8,061,417 | 97,987 | 92.02% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-26 | 90.14%a |
| 2025 | 2025-05-29 | 95.91%b |
| 2024 | 2024-05-29 | 78.64%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “Abstentions will be counted towards the vote total for Proposals 2 and 3 and will have the same effect as "Against" votes in each case.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 24 : 1 |
|---|---|
| CEO total compensation | $7,834,045 |
| Median employee compensation | $331,187 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Marianne De Backer | Director | 2026-04-29 | D | 233,532 | $0 | $0 | Common | Form 4 ↗ |
| Marianne De Backer | Director | 2026-04-29 | A | 233,532 | 0 | 0 | Common | Form 4 ↗ |
| Vicki Sato | Director | 2026-05-01 | D | 22,000 | 10 | 221,025 | Common | Form 4 ↗ |
| Janet Napolitano | Director | 2026-05-27 | A | 16,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Norbert Bischofberger | Director | 2026-05-27 | A | 16,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ramy Farid | Director | 2026-05-27 | A | 16,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey S. Hatfield | Director | 2026-05-27 | A | 16,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert More | Director | 2026-05-27 | A | 16,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Janet Napolitano | Director | 2026-05-27 | A | 8,000 | 0 | 0 | RSU | Form 4 ↗ |
| Jeffrey S. Hatfield | Director | 2026-05-27 | A | 8,000 | 0 | 0 | RSU | Form 4 ↗ |
| Norbert Bischofberger | Director | 2026-05-27 | A | 8,000 | 0 | 0 | RSU | Form 4 ↗ |
| Ramy Farid | Director | 2026-05-27 | A | 8,000 | 0 | 0 | RSU | Form 4 ↗ |
| Robert More | Director | 2026-05-27 | A | 8,000 | 0 | 0 | RSU | Form 4 ↗ |
| Elliott Sigal | Director | 2026-05-27 | A | 16,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Elliott Sigal | Director | 2026-05-27 | A | 8,000 | 0 | 0 | RSU | Form 4 ↗ |
| Brent Sabatini | SVP, Chief Accounting Officer | 2026-06-01 | D | 379 | 9 | 3,582 | Common | Form 4 ↗ |
| Janet Napolitano | Director | 2026-06-01 | D | 3,200 | 9 | 30,240 | Common | Form 4 ↗ |
| Timothy Coughlin | Director | 2026-06-09 | A | 8,000 | 0 | 0 | RSU | Form 4 ↗ |
| Timothy Coughlin | Director | 2026-06-09 | A | 8,000 | 0 | 0 | RSU | Form 4 ↗ |
| Timothy Coughlin | Director | 2026-06-09 | A | 16,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Coughlin | Director | 2026-06-09 | A | 16,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert More | Director | 2026-08-11 | A | 8,000 | 0 | 0 | Common, indirect | Form 4 ↗ |
| Robert More | Director | 2026-08-11 | D | 8,000 | 0 | 0 | Common | Form 4 ↗ |
| Suzanne Louise Topalian | Director | 2026-10-27 | A | 9,462 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Suzanne Louise Topalian | Director | 2026-10-27 | A | 16,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Suzanne Louise Topalian | Director | 2026-10-27 | A | 4,731 | 0 | 0 | RSU | Form 4 ↗ |
| Suzanne Louise Topalian | Director | 2026-10-27 | A | 8,000 | 0 | 0 | RSU | Form 4 ↗ |
| Vanina de Verneuil | EVP, General Counsel, Corp Sec | 2026-11-02 | D | 1,343 | 11 | 15,222 | Common | Form 4 ↗ |
| Vanina de Verneuil | EVP, General Counsel, Corp Sec | 2026-11-03 | D | 2,407 | 11 | 26,718 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (64 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Marianne De Backer. DEF 14A, filed 2026-04-16. Section “Summary Compensation Table” · page 39. As printed: 7,834,045. View filing ↗
- Section 01, Mark Eisner. DEF 14A, filed 2026-04-16. Section “Summary Compensation Table”. As printed: 2,371,484. View filing ↗
- Section 01, Jason O'Byrne. DEF 14A, filed 2026-04-16. Section “Summary Compensation Table”. As printed: 1,951,828. View filing ↗
- Section 01, Vanina de Verneuil. DEF 14A, filed 2026-04-16. Section “Summary Compensation Table”. As printed: 1,690,784. View filing ↗
- Section 03, Vanina de Verneuil OPTION. DEF 14A, filed 2026-04-16. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Marianne De Backer M.Sc. OPTION. DEF 14A, filed 2026-04-16. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Marianne De Backer M.Sc. RSU. DEF 14A, filed 2026-04-16. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Vanina de Verneuil RSU. DEF 14A, filed 2026-04-16. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Eisner OPTION. DEF 14A, filed 2026-04-16. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Mark Eisner RSU. DEF 14A, filed 2026-04-16. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Jason O'Byrne RSU. DEF 14A, filed 2026-04-16. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Jason O'Byrne OPTION. DEF 14A, filed 2026-04-16. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-16. Section “CEO Pay Ratio”. As printed: 24 : 1. View filing ↗
- Section 08, Elliott Sigal. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 187,505. View filing ↗
- Section 08, Vicki Sato. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 184,975. View filing ↗
- Section 08, Jeffrey S. Hatfield. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 184,645. View filing ↗
- Section 08, Robert More. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 182,860. View filing ↗
- Section 08, Saira Ramasastry. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 180,126. View filing ↗
- Section 08, Norbert Bischofberger. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 176,661. View filing ↗
- Section 08, Ramy Farid. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 164,975. View filing ↗
- Section 08, Janet Napolitano. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 159,975. View filing ↗
- Section 08, George Scangos. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 39,557. View filing ↗
- Section 08, Robert Nelsen. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 22,665. View filing ↗
- Section 08, Marianne De Backer. DEF 14A, filed 2026-04-16. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Marianne De Backer 2026-04-29. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marianne De Backer 2026-04-29. Form 4, filed 2026-04-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vicki Sato 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Janet Napolitano 2026-05-27. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Norbert Bischofberger 2026-05-27. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ramy Farid 2026-05-27. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey S. Hatfield 2026-05-27. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert More 2026-05-27. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Janet Napolitano 2026-05-27. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey S. Hatfield 2026-05-27. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Norbert Bischofberger 2026-05-27. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ramy Farid 2026-05-27. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert More 2026-05-27. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliott Sigal 2026-05-27. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Elliott Sigal 2026-05-27. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Brent Sabatini 2026-06-01. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Janet Napolitano 2026-06-01. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Coughlin 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Coughlin 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Coughlin 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Timothy Coughlin 2026-06-09. Form 4, filed 2026-06-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert More 2026-08-11. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert More 2026-08-11. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suzanne Louise Topalian 2026-10-27. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suzanne Louise Topalian 2026-10-27. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suzanne Louise Topalian 2026-10-27. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suzanne Louise Topalian 2026-10-27. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vanina de Verneuil 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Vanina de Verneuil 2026-11-03. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-28. Item 5.07 · say-on-pay result. As reported: 90.14% (votes for as printed: 108,453,963). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-29. Item 5.07 · say-on-pay result. As reported: 95.91% (votes for as printed: 100,486,810). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-29. Item 5.07 · say-on-pay result. As reported: 78.64% (votes for as printed: 83,922,789). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 704,144 + equity 316,160 + all other 0 = 1,020,304, summed across the director compensation table rows.
- BridgeBio Pharma, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in BridgeBio Pharma's own proxy. As printed: 14,944,585. View filing ↗
- Janux Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Janux Therapeutics's own proxy. As printed: 13,506,231. View filing ↗
- Apellis, Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Apellis's own proxy. As printed: 10,957,451. View filing ↗
- Vir Biotechnology, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Vir Biotechnology, Inc.'s own proxy. As printed: 7,834,045. View filing ↗
- Replimune Group, Section 10b CEO total. DEF 14A, filed 2026-07-29. CEO total compensation as printed in Replimune Group's own proxy. As printed: 5,845,982. View filing ↗